Abstract: Objective To investigate the role of a clinical pharmacist in the diagnosis and treatment of skin pigmentation induced by polymyxin B. Methods A clinical pharmacist participated in the diagnosis and treatment of a patient with pigmentation. According to the changes of the patient's condition, the clinical pharmacist and the clinician consulted each other, analyzed the causes of the adverse reactions, raised pharmaceutical suggestions, and worked out an appropriate treatment plan. After discharge, the patient was followed up by the clinical pharmacist to track the prognosis. Results In the course of diagnosis and treatment, doctors adopted the advice of the clinical pharmacist that skin pigmentation was caused by polymyxin B. The symptoms did not aggravate after discontinuation, but the skin color base line remained unchanged. Conclusion When polymyxin B is used, the patient can take into account the adverse reactions caused by this drug, and the clinical physician and the clinical pharmacist need to weigh the advantages and disadvantages of using the polymyxin B to balance the efficacy and adverse events. At the same time, careful consideration should be given to the combination of other drugs that may lead to skin-like symptoms. Clinical pharmacists are expected to combine their expertise with clinical practice, improve the diagnosis of disease and the level of medication in order to ensure the safety of patients..

Key words: skin pigmentation, polymyxin B, adverse reactions, klebsiella pneumoniae